drugset / Trial / NCT06472479
LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
Not yet recruiting
66 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
A prospective, two-cohort, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-M61S and LCAR-M61D in patients with relapsed/refractory multiple myeloma.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2028-08-22
- Completion
- 2029-10-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-M61D | Cell therapy | — | Intravenous |
| Subject | LCAR-M61S | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |